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Aims In the Digitalis Investigation Group (DIG) trial, digoxin reduced mortality or hospitalization due to heart failure (HF)
in several pre-specified high-risk subgroups of HF patients, but data on protocol-specified 2-year outcomes were not
presented. In the current study, we examined the effect of digoxin on HF death or HF hospitalization and all-cause




In the DIG trial, 6800 ambulatory patients with chronic HF, normal sinus rhythm, and LVEF ≤45% (mean age
64 years, 26% women, 17% non-whites) were randomized to receive digoxin or placebo. The three high-risk
groups were defined as NYHA class III– IV symptoms (n ¼ 2223), LVEF ,25% (n ¼ 2256), and cardiothoracic
ratio (CTR) .55% (n ¼ 2345). In all three high-risk subgroups, compared with patients in the placebo group,
those in the digoxin group had a significant reduction in the risk of the 2-year composite endpoint of HF mortality
or HF hospitalization: NYHA III– IV [hazard ratio (HR) 0.65; 95% confidence interval (CI) 0.57–0.75; P , 0.001],
LVEF ,25% (HR 0.61; 95% CI 0.53–0.71; P , 0.001), and CTR .55% (HR 0.65; 95% CI 0.57–0.75; P , 0.001).
Digoxin-associated HRs (95% CI) for 2-year all-cause mortality or all-cause hospitalization for subgroups with
NYHA III– IV, LVEF ,25%, and CTR .55% were 0.88 (0.80–0.97; P ¼ 0.012), 0.84 (0.76–0.93; P ¼ 0.001), and
0.85 (0.77–0.94; P ¼ 0.002), respectively.
Conclusions Digoxin improves outcomes in chronic HF patients with NYHA class III– IV, LVEF ,25%, or CTR .55%, and should
be considered in these patients.
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Introduction
In the Digitalis Investigation Group (DIG) trial, the largest rando-
mized clinical trial (RCT) of digoxin efficacy in heart failure (HF),
digoxin reduced the combined endpoint of hospitalization due to
worsening HF and death due to progressive HF, but had no
association with all-cause mortality.1 Taken together with the find-
ings from the Prospective Randomized Study of Ventricular Func-
tion and Efficacy of Digoxin (PROVED) and Randomized
Assessment of Digoxin on Inhibitors of the Angiotensin Convert-
ing Enzyme (RADIANCE),2,3 this cumulative evidence was used
by the US Food and Drug Administration (FDA) to approve
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digoxin for use in HF in 1997 and, subsequently, all major national
HF guidelines recommended the use of digoxin in HF.4,5 The out-
comes used by the FDA and presented in the package insert for
Lanoxinw tablets were the combined endpoints of death or hospi-
talization due to HF and death or hospitalization due to all causes
during the first 2 years of follow-up.6 The DIG investigators
hypothesized the effect of digoxin to be more pronounced
during the first 2 years after randomization.7 These analyses also
included three high-risk subgroups.6 The DIG report presented
the effect of digoxin on HF death or HF hospitalization during
the entire follow-up in these three subgroups.1 However, baseline
characteristics of these high-risk subgroups and the effect of
digoxin on 2-year outcomes have not been previously published
in the peer-reviewed medical literature. The objective of the
current study was to examine the effect of digoxin on 2-year HF
death or HF hospitalization and total death or total hospitalization
in high-risk HF patients in the DIG trial.
Methods
Study design and patients
The DIG trial was a placebo-controlled double-blind RCT of digoxin in
HF. The detailed description of the rationale, design, implementation,
patient characteristics, and results of the DIG trial has been reported
previously.1,8 Briefly, the DIG trial enrolled 7788 ambulatory chronic
HF patients in normal sinus rhythm from 302 centres in the USA
and Canada from 1991 to 1993. Patients were randomized to
receive either digoxin or placebo. Of these patients, 6800 had LVEF
≤45% (main study) and 988 had LVEF .45% (ancillary study).1,9
Most patients were receiving background therapy with angiotensin-
converting enzyme (ACE) inhibitors and diuretics. Although data on
beta-blocker use were not collected, the rate of beta-blocker use
would be expected to be low, as these drugs were not yet approved
for use in HF. The current study was based on a public-use copy of the
DIG data obtained from the National Heart, Lung, and Blood Institute,
which also sponsored the DIG trial.
High-risk patients
High risk was defined as NYHA class III– IV symptoms, LVEF ,25%, or
cardiothoracic ratio (CTR) .55%. Although the NYHA subgroup was
specifically mentioned in the DIG trial protocol, both the DIG report
and FDA analyses included the other two subgroups.1,6 Because the
FDA determines the requirements for drug packaging, including find-
ings of subgroup analyses,10 we used all three high-risk subgroups
for the purpose of the current study. Findings from the RADIANCE
and PROVED trials suggested that discontinuation of digoxin tended
to worsen NYHA class symptoms, reduce LVEF, and increase the
CTR.3 Therefore, it was expected that digoxin would be most effective
in HF patients with higher NYHA class symptoms, lower LVEF, and
larger hearts. To compare the effect of digoxin in low-risk HF patients,
we assembled a cohort that excluded patients with any of the three
high-risk characteristics, namely NHYA class III– IV symptoms, LVEF
,25%, or CTR .55%.
Outcomes
The primary outcome of the DIG trial was all-cause mortality during a
median follow-up of 37.9 months. Vital status of all patients was col-
lected up to 31 December 1995 and was 98.9% complete.11
Because the effect of digoxin was expected to be more pronounced
in the first 2 years after randomization, the DIG trial protocol pre-
specified separate analysis of the effect of digoxin on mortality and
HF hospitalization during that period.7 Outcomes of interest for the
current analysis were combined endpoints of HF mortality or HF hos-
pitalization and all-cause mortality or all-cause hospitalization during
the first 2 years after randomization.6
Statistical analysis
Baseline characteristics of high-risk HF patients were compared using
Pearson’s x2 and Wilcoxon rank sum tests. Kaplan–Meier analysis and
Cox proportional hazards analyses were used to determine the effect
of digoxin on various outcomes. Using a serum digoxin concentration
(SDC) cut-off of 0.5–0.9 ng/mL and ≥1 ng/mL as low and high SDCs,
respectively,12 we examined the association of low and high SDCs
with the combined endpoints of 2-year all-cause mortality or all-cause
hospitalization and 2-year HF mortality or HF hospitalization. We
then repeated our analysis in low-risk HF patients. All statistical tests
were two-tailed, with P-values ,0.05 considered significant. SPSS-18
for Windows (Chicago, IL, USA) was used for statistical analysis.
Results
Baseline characteristics
Overall, DIG trial participants included 4367 high-risk patients.
These patients had a mean age of 64 (SD +11) years, 26%
were female, and 17% were non-whites. Of these patients, 2223
(51%), 2256 (52%), and 2345 (54%) had NYHA class III– IV symp-
toms, LVEF ,25%, and CTR .55%, respectively. Baseline charac-
teristics of patients receiving digoxin and placebo were similar in all
three high-risk subgroups, except for a lower prevalence of dia-
betes among patients with LVEF ,25% receiving digoxin (Table 1).
Two-year heart failure mortality or heart
failure hospitalization
Compared with patients receiving placebo, digoxin-associated
hazard ratios (HRs) for the combined endpoint of 2-year HF
death or HF hospitalization in subgroups with NYHA class III– IV
symptoms, LVEF ,25%, and CTR .55% were 0.65 [95% confi-
dence interval (CI) 0.57–0.75; P , 0.001], 0.61 (95% CI 0.53–
0.71; P , 0.001), and 0.65 (95% CI 0.57–0.75; P , 0.001), respect-
ively (Table 2 and Figure 1). Of the 4367 high-risk patients, 3079 had
data on SDC, and digoxin significantly reduced the risk of HF death
or HF hospitalization both at low SDC (HR 0.56; 95% CI 0.46–
0.68; P , 0.001) and at high SDC (HR 0.72; 95% CI 0.59–0.87;
P ¼ 0.001; data not presented in the tables).
Two-year all-cause mortality or all-cause
hospitalization
Compared with the patients receiving placebo, digoxin-associated
HRs for the combined endpoint of 2-year total death or all-cause
hospitalization in subgroups with NYHA class III– IV symptoms,
LVEF ,25%, and CTR .55% were 0.88 (95% CI 0.80–0.97;
P ¼ 0.012), 0.84 (95% CI 0.76–0.93; P ¼ 0.001), and 0.85 (95%
CI 0.77–0.94; P ¼ 0.002), respectively (Table 2 and Figure 2).
Digoxin significantly reduced the risk of all-cause death or all-cause
hospitalization at low SDC in those in the high-risk group
(HR 0.76; 95% CI 0.67–0.86; P , 0.001), but not at high SDC
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Table 1 Baseline patient characteristics in subgroups of high-risk heart failure patients in the Digitalis Investigation Group trial
Variables, mean+ SD or n (%) NYHA class III–IV LVEF <25% Cardiothoracic ratio >55%
Digoxin (n 5 1118) Placebo (n 5 1105) Digoxin (n 5 1127) Placebo (n 5 1129) Digoxin (n 5 1175) Placebo (n 5 1170)
Age (years) 65+ 11 65+ 11 63+ 11 63+ 11 64+ 11 65+ 11
Female 305 (27%) 312 (28%) 209 (19%) 203 (18%) 399 (34%) 389 (33%)
Non-white 167 (15%) 150 (14%) 180 (16%) 195 (17%) 279 (24%) 280 (24%)
Body mass index (kg/m2) 27+ 6 27+ 6 27+ 5 27+ 5 27+ 6 27+ 6
Duration of HF (months) 35+ 41 32+ 38 31+ 36 32+ 34 30+ 38 30+ 37
LVEF (%) 27+ 9 26+ 9 19+ 4 18+ 4 27+ 9 27+ 9
LVEF ,25% 468 (41%) 487 (44%) 1127 (100%) 1129 (100%) 509 (43%) 509 (44%)
Cardiothoracic ratio 0.55+ 0.08 0.55+ 0.07 0.61+ 0.05 0.61+ 0.05 0.55+ 0.07 0.55+ 0.07
Cardiothoracic ratio .55% 499 (45%) 487 (44%) 509 (45%) 509 (45%) 1175 (100%) 1170 (100%)
NYHA functional class
I 0 (0%) 0 (0%) 117 (10%) 108 (10%) 133 (11%) 110 (9%)
II 0 (0%) 0 (0%) 542 (48%) 534 (47%) 543 (46%) 573 (49%
III 1042 (93%) 1039 (94%) 428 (38%) 443 (39%) 449 (38%) 444 (38%)
IV 76 (7%) 66 (6%) 40 (4%) 44 (4%) 50 (4%) 43 (4%)
Signs or symptoms of HF
Dyspnoea at rest 454 (41%) 466 (42%) 295 (26%) 294 (26%) 339 (29%) 348 (30%)
Dyspnoea on exertion 1046 (94%) 1027 (93%) 883 (50%) 887 (79%) 904 (77%) 940 (80%)
Jugular venous distension 265 (24%) 277 (25%) 195 (17%) 215 (19%) 244 (21%) 243 (21%)
Pulmonary râles 343 (31%) 323 (29%) 237 (21%) 220 (20%) 292 (25%) 288 (25%)
Lower extremity oedema 358 (32%) 331 (30%) 253 (22%) 224 (20%) 316 (27%) 347 (30%)
Pulmonary congestion 272 (24%) 267 (24%) 217 (19%) 206 (18%) 280 (24%) 276 (24%)
No. of signs or symptoms of HFa
0 0 (0%) 2 (0.2%) 15(1.3%) 12 (1.1%) 10 (0.9%) 7 (0.6%)
1 2 (0.2%) 4 (0.4%) 17 (1.5%) 16 (1.4%) 19 (1.6%) 15 (1.3%)
2 27 (2.4%) 34 (3.1%) 53 (4.7%) 51 (4.5%) 54 (4.6%) 50 (4.3%)
3 57 (5.1%) 74 (6.7%) 84 (7.5%) 82 (7.3%) 79 (7.3%) 85 (6.7%)
≥4 1032 (92.3%) 991 (89.7%) 958 (85%) 968 (85.7%) 1013 (86.6%) 1013 (86.2%)
Co-morbid conditions
Prior myocardial infarction 706 (63%) 718 (65%) 679 (60%) 690 (61%) 655 (56%) 658 (56%)
Current angina pectoris 394 (35%) 380 (34%) 287 (26%) 265 (24%) 261 (24%) 283 (22%)
Hypertension 522 (47%) 497 (45%) 489 (43%) 459 (41%) 621 (53%) 625 (53%)
Diabetes mellitus 381 (34%) 367 (33%) 312 (28%)* 267 (24%)* 354 (30%) 359 (31%)
Chronic kidney disease 576 (52%) 593 (54%) 507 (45%) 509 (45%) 567 (48%) 562 (48%)
Primary cause of HF
Ischaemic 787 (70%) 770 (70%) 747 (66%) 738 (65%) 728 (62%) 705 (60%)
Hypertensive 92 (8%) 84 (8%) 95 (8%) 85 (8%) 150 (13%) 162 (14%)
Idiopathic 167 (15%) 170 (15%) 213 (19%) 215 (19%) 217 (19%) 203 (17%)
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Table 1 Continued
Variables, mean+ SD or n (%) NYHA class III–IV LVEF <25% Cardiothoracic ratio >55%
Digoxin (n 5 1118) Placebo (n 5 1105) Digoxin (n 5 1127) Placebo (n 5 1129) Digoxin (n 5 1175) Placebo (n 5 1170)
Medications
Pre-trial digoxin use 532 (48%) 517 (47%) 533 (47%) 577 (51%) 544 (47%) 573 (49%)
ACE inhibitors 1060 (95%) 1036 (94%) 1077 (96%) 1082 (96%) 1104 (94%) 1110 (95%)
Diuretics 983 (88%) 969 (88%) 950 (84%) 957 (85%) 1009 (86%) 1017 (87%)
Nitroglycerines 578 (52%) 568 (51%) 460 (41%) 482 (43%) 531 (45%) 534 (50%)
Dose of study medication (mg/dL) 0.23+ 0.07 0.23+ 0.08 0.24+ 0.07 0.24+ 0.07 0.24+ 0.08 0.24+ 0.08
Heart rate (b.p.m.) 81 +13 82+ 13 81+ 13 81+ 13 80+ 13 81+ 13
Blood pressure (mmHg)
Systolic 124+ 20 123+ 21 122+ 19 121+ 19 125+ 21 126+ 21
Diastolic 74+ 12 74+ 12 75+ 12 74+ 11 75+ 13 75+ 12
Serum creatinine (mg/dL) 1.33+ 0.40 1.34+ 0.41 1.3+ 0.37 1.3+ 0.36 1.28+ 0.38 1.29+ 0.37
HF, heart failure.
*P-value ,0.05.
aClinical signs or symptoms included rales, elevated jugular venous pressure, peripheral oedema, dyspnoea at rest or on exertion, orthopnoea, limitation of activity, S3 gallop, and radiological evidence of pulmonary congestion present in past or
present.
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Table 2 Combined mortality or hospitalization endpoints during the first 2 years after randomization by digoxin and placebo in subgroups of high-risk heart failure
patients in the Digitalis Investigation Group trial
Outcomes % (events) Absolute risk differencea Hazard ratio (95% CI) P-value
Digoxin Placebo
NYHA class III– IV (n ¼ 1118) (n ¼ 1105)
HF mortality or HF hospitalization 29% (329) 40% (445) –11% 0.65 (0.57–0.75) ,0.001
All-cause mortality or all-cause hospitalization 70% (779) 72% (795) –2% 0.88 (0.80–0.97) 0.012
LVEF ,25% (n ¼ 1127) (n ¼ 1129)
HF mortality or HF hospitalization 27% (304) 39% (444) –12% 0.61 (0.53–0.71) ,0.001
All-cause mortality or all-cause hospitalization 64% (716) 68% (767) –4% 0.84 (0.76–0.93) 0.001
Cardiothoracic ratio .55% (n ¼ 1175) (n ¼ 1170)
HF mortality or HF hospitalization 29% (336) 40% (465) –11% 0.65 (0.57–0.75) ,0.001
All-cause mortality or all-cause hospitalization 65% (764) 69% (805) –4% 0.85 (0.77–0.94) 0.002
High risk (any of the above) (n ¼ 2191) (n ¼ 2176)
HF mortality or HF hospitalization 26% (566) 36% (783) –10% 0.66 (0.59–0.73) ,0.001
All-cause mortality or all-cause hospitalization 64% (1391) 67% (1459) –3% 0.87 (0.81–0.94) ,0.001
CI, confidence interval; HF, heart failure.







(HR 0.95; 95% CI 0.84–1.08; P ¼ 0.437; data not presented in
the tables).
Other 2-year outcomes
Digoxin significantly reduced the risk of HF and all-cause hospital-
ization in all three subgroups of high-risk HF patients (Table 3). In
patients with CTR .55%, digoxin significantly reduced HF mortal-
ity (HR 0.71; 95% CI 0.56–0.91; P ¼ 0.007; Table 3), but this effect
was not significant in the other high-risk subgroups. The associa-
tions of digoxin with other outcomes are displayed in Table 3.
These associations were similar during the entire length of the
study follow-up.
Two-year outcomes in low-risk heart
failure patients
The combined endpoint of 2-year HF death or HF hospitalization
occurred in 14% and 18% of low-risk chronic HF patients receiving
digoxin and placebo, respectively (HR 0.76; 95% CI 0.62–0.94;
P ¼ 0.009; Table 4). Digoxin had no significant effect on any
other outcomes, including the two combined endpoints of all-
cause mortality or all-cause hospitalization (HR 1.07; 95% CI
0.96–1.20; P ¼ 0.221) and cardiovascular mortality or HF hospital-
ization (HR 0.87; 95% CI 0.73–1.03; P ¼ 0.110; Table 4). Among
the 2425 low-risk patients, 1785 had available data on SDC,
and digoxin significantly reduced the risk of HF death or HF hos-
pitalization at low SDC (HR 0.54; 95% CI 0.38–0.77; P ¼ 0.001),
but not at high SDC (HR 1.02; 95% CI 0.72–1.44; P ¼ 0.931).
Discussion
Findings from the current study demonstrate that over half of
chronic HF patients in the DIG trial had severe and more advanced
disease as evidenced by the presence of NYHA III–IV symptoms,
LVEF ,25%, or CTR .55%, and that digoxin significantly improved
outcomes in all three high-risk subgroups. The effect of digoxin was
most pronounced on the combined endpoints of HF mortality or
Figure 1 Kaplan–Meier plots for heart failure (HF) mortality or HF hospitalization by treatment groups in high-risk patients with chronic HF
in the DIG trial: (A) NYHA class III– IV, (B) LVEF ,25%, and (C ) cardiothoracic ratio .55%. CI, confidence interval.
Figure 2 Kaplan–Meier plots for all-cause mortality or all-cause hospitalization by treatment groups in high-risk patients with chronic heart
failure (HF) in the DIG trial: (A) NYHA class III– IV, (B) LVEF ,25%, and (C) cardiothoracic ratio .55%. CI, confidence interval.
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HF hospitalization, and could be observed regardless of SDC and in
those without the high-risk characteristics. However, the effect on
the combined endpoints of total mortality or total hospitalization
was primarily observed in those receiving digoxin at low SDC. To
the best of our knowledge, this is the first report on the effect of
digoxin outcomes in the three pre-specified high-risk subgroups
during the protocol-specified 2 years of follow-up.
Digoxin is the only positive inotrope that does not increase
mortality.1 Furthermore, when used in lower doses resulting in
lower SDC, it may also significantly reduce total mortality.12– 14 Im-
portantly, digoxin significantly reduces HF hospitalization, regard-
less of SDC, although the magnitude of this effect is greater at
lower SDC.12 The superior effect of low-dose digoxin, also
observed in the current analysis, has been attributed to its neuro-
hormonal inhibitory effects.15 –19 The lack of a significant effect on
individual endpoints of total mortality is probably due to the high
digoxin doses and the high SDC targets used in the DIG trial.1,7,8
Yet, in the DIG trial, there was significant reduction in total
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 3 Individual mortality or hospitalization endpoints during the first 2 years after randomization by digoxin and
placebo in subgroups of high-risk heart failurepatients in the Digitalis Investigation Group trial






NYHA class III– IV (n ¼ 1118) (n ¼ 1105)
All-cause mortality 30% (340) 30% (330) 0% 1.00 (0.86–1.16) 0.988
CV mortality 25% (276) 25% (277) 0% 0.97 (0.82–1.14) 0.686
HF mortality 12% (130) 13% (147) –1% 0.86 (0.68–1.09) 0.204
All-cause hospitalization 61% (678) 64% (709) –3% 0.86 (0.78–0.96) 0.005
CV hospitalization 47% (525) 53% (590) –6% 0.79 (0.70–0.88) ,0.001
HF hospitalization 26% (290) 37% (404) –11% 0.63 (0.54–0.74) ,0.001
All-cause mortality or HF hospitalization 44% (491) 51% (565) –7% 0.76 (0.68–0.86) ,0.001
CV mortality or HF hospitalization 39% (441) 48% (533) –9% 0.73 (0.64–0.82) ,0.001
LVEF ,25% (n ¼ 1127) (n ¼ 1129)
All-cause mortality 29% (321) 29% (329) 0% 0.96 (0.82–1.12) 0.600
CV mortality 24% (273) 25% (287) –1% 0.94 (0.79–1.10) 0.433
HF mortality 10% (116) 13% (144) –3% 0.79 (0.62–1.01) 0.062
All-cause hospitalization 54% (603) 61% (683) –7% 0.79 (0.71–0.88) ,0.001
CV hospitalization 42% (475) 50% (569) –8% 0.75 (0.66–0.84) ,0.001
HF hospitalization 24% (271) 36% (406) –12% 0.60 (0.51–0.70) ,0.001
All-cause mortality or HF hospitalization 41% (466) 50% (568) –9% 0.73 (0.65–0.83) ,0.001
CV mortality or HF hospitalization 38% (433) 48% (542) –10% 0.71 (0.63–0.81) ,0.001
Cardiothoracic ratio .55% (n ¼ 1175) (n ¼ 1170)
All-cause mortality 29% (335) 28% (332) +1% 0.99 (0.85–1.16) 0.933
CV mortality 23% (274) 24% (277) –1% 0.97 (0.82–1.15) 0.759
HF mortality 9% (107) 13% (148) –4% 0.71 (0.56–0.91) 0.007
All-cause hospitalization 57% (667) 62% (727) –5% 0.83 (0.74–0.92) ,0.001
CV hospitalization 44% (521) 53% (615) –9% 0.76 (0.68–0.86) ,0.001
HF hospitalization 27% (311) 36% (421) –9% 0.67 (0.58–0.77) ,0.001
All-cause mortality or HF hospitalization 43% (506) 50% (579) –7% 0.79 (0.70–0.89) ,0.001
CV mortality or HF hospitalization 40% (465) 46% (543) –6% 0.77 (0.68–0.87) ,0.001
High risk (any of the above) (n ¼ 2191) (n ¼ 2176)
All-cause mortality 26% (570) 26% (567) 0% 0.99 (0.88–1.11) 0.806
CV mortality 21% (467) 22% (475) –1% 0.96 (0.85–1.10) 0.574
HF mortality 9% (192) 11% (235) –2% 0.80 (0.66–0.97) 0.023
All-cause hospitalization 55% (1204) 60% (1309) –5% 0.84 (0.78–0.91) ,0.001
CV hospitalization 43% (935) 49% (1076) –6% 0.79 (0.72–0.86) ,0.001
HF hospitalization 23% (509) 33% (718) –10% 0.64 (0.57–0.72) ,0.001
All-cause mortality or HF hospitalization 39% (859) 46% (1008) –7% 0.77 (0.70–0.84) ,0.001
CV mortality or HF hospitalization 36% (784) 44% (946) –8% 0.75 (0.68–0.82) ,0.001
CI, confidence interval; CV, cardiovascular; HF, heart failure.
aAbsolute risk differences were calculated by subtracting percentage events in patients receiving placebo from those in patients receiving digoxin.
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mortality during the first year of follow-up,20 and a trend toward
reduced risk of death due to progressive HF in patients receiving
digoxin.1 The lack of significant reduction in HF death in the
NYHA class III– IV subgroup may be explained by the preferential
effect of digoxin on HF death. As HF advances, death due to pump
failure becomes more common than sudden cardiac death.21,22
Unlike CTR .55% and LVEF ,25%, which may indicate biologic-
ally advanced HF, NYHA class III– IV symptoms may occur in both
early and advanced stage HF. Fewer HF deaths in NYHA class III–IV
patients may explain a weaker effect of digoxin in these patients.
Despite many advances in drug and device therapy, HF remains a
leading cause of hospitalization for patients.23 Mortality and rehos-
pitalization rates within 60–90 days of hospital discharge approach
15% and 30%, respectively.24 Yet, findings from both contempor-
ary HF registries and RCTs suggest that digoxin is underutilized
in HF.25,26 Although the lack of mortality benefit of digoxin is
often cited as a reason, drugs without mortality benefit play im-
portant roles in HF care.5,27,28 Another reason for underutilization
of digoxin is that DIG trial patients were not receiving beta-
blockers and thus those findings may not be generalizable to con-
temporary HF patients receiving beta-blockers. However, most HF
patients in the beta-blocker trials were receiving digoxin and it
could be argued that the results from those beta-blocker trials
may not be generalized to contemporary HF patients not receiving
digoxin. Most patients in the early RCTs of ACE inhibitors and al-
dosterone antagonists did not receive beta-blockers,29,30 and yet
these drugs have later been shown to improve outcomes in HF
patients receiving beta-blockers.26,31 Given the magnitude of the
effect of digoxin on HF hospitalization in the high-risk group
observed in the current study (36% relative reduction and 10% ab-
solute reduction; Table 3), these findings would probably be repli-
cated in contemporary HF patients. This optimism was voiced in
recent clinical research that found the effect of digoxin in the
DIG trail to be similar to that of ivabradine in the Systolic Heart
failure treatment with If inhibitor ivabradine Trial (SHIFT).
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Finally, digoxin is inexpensive and safe, and may also reduce HF
hospitalization in HF with preserved LVEF.9,33,34
The effect of digoxin on HF death and hospitalization during the
first 2 years of follow-up was similar to that observed during the
entire follow-up presented in the original DIG report.1 This is re-
markable considering that in the Studies of Left Ventricular Dys-
function (SOLVD) trial enalapril had no effect on mortality after
the first 2 years of follow-up, and in the Candesartan in Heart
failure Assessment of Reduction in Mortality and morbidity
(CHARM) trial, most of the cardiovascular death reduction oc-
curred during the first year of follow-up.29,35 In addition to pre-
senting baseline characteristics of the three pre-specified
high-risk subgroups, the current study is also distinguished by its
focus on the outcomes during the protocol-specified 2 years of
follow-up which was the basis of the approval of digoxin for use
in HF.6,7 The new US healthcare reform law has targeted 30-day
all-cause hospital readmission as a key outcome to reduce the
cost of Medicare.36 We observed that the rate of HF hospitaliza-
tion was twice as high among patients in the high-risk group as
in those in the low-risk group (Tables 3 and 4). Taken together
with the fact that worsening HF is a key reason for hospital admis-
sion and readmission in patients with HF,37 and that the rate of HF
hospitalization has not declined in the past decades,38 these find-
ings suggest that digoxin may play a role in reducing hospital admis-
sion in high-risk HF patients.
Our study has several limitations. DIG trial participants were
predominantly white men, with normal sinus rhythm, and did not
receive beta-blockers or aldosterone antagonists. In addition, the
high dose and high SDC target used in the DIG trial may have
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Individual or combined endpoints during the first 2 years after randomization by digoxin and placebo in
subgroups of low-risk heart failurepatients in the Digitalis Investigation Group trial





Digoxin (n 5 1201) Placebo (n 5 1224)
Low-risk (NYHA class I– II symptoms,
EF .25%, and CTR ,55%)
HF mortality or HF hospitalization 14% (167) 18% (216) –4% 0.76 (0.62–0.94) 0.009
All-cause mortality or all-cause
hospitalization
52% (623) 49% (601) +3% 1.07 (0.96–1.20) 0.221
All-cause mortality 12% (147) 13% (158) –1% 0.95 (0.76–1.19) 0.632
CV mortality 10% (119) 9% (111) +1% 1.09 (0.84–1.41) 0.512
HF mortality 3% (32) 3% (41) 0% 0.80 (0.50–1.26) 0.330
All-cause hospitalization 47% (564) 45% (552) +2% 1.06 (0.94–1.19) 0.355
CV hospitalization 33% (393) 33% (405) 0% 0.98 (0.86–1.13) 0.803
HF hospitalization 13% (155) 17% (202) –4% 0.76 (0.62–0.94) 0.009
All-cause mortality or HF hospitalization 22% (263) 25% (307) –3% 0.85 (0.72–1.00) 0.046
CV mortality or HF hospitalization 20% (240) 22% (273) –2% 0.87 (0.73–1.03) 0.110
CI, confidence interval; CTR, cardiothoracic ratio; CV, cardiovascular; HF, heart failure.
aAbsolute risk differences were calculated by subtracting percentage events in patients receiving placebo from those in patients receiving digoxin.
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led to a higher SDC, thus attenuating the effect of digoxin on out-
comes. Therefore, there is a need to examine the effect of
low-dose digoxin on outcomes in contemporary HF patients
with reduced and preserved LVEF in a well-designed RCT with
substantial participation of women and minorities.
In conclusion, digoxin significantly reduces the risk of clinically
important composite endpoints of mortality or hospitalizations in
ambulatory chronic HF patients with NYHA class III– IV symptoms,
LVEF ,25%, or CTR .55%, and should be considered in these
patients.
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